fbpx

Year

2015
Lund, Sweden, (PRNEWSWIRE) May 13, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received the Frost & Sullivan 2015 Growth Capital Investment Award for outstanding achievement and superior performance in the area of technological innovation and strategic product development in...
You can now apply for a MIT Fellowship at The McGovern Institute for Brain Research, Cambridge, Massachusetts
Denmark's answer to the Nobel Prize, The Brain Prize is founded and 100 % funded by the Lundbeck Foundation. It goes to two German and two American researchers. The price, which is 1 million Euro, is presented by HRH Crown Prince Frederik on May 7 in Copenhagen . 
Primary endpoint of preventing delayed CINV met with high significanceCambridge, UK - 6th May 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention...
Lund, Sweden, (PRNEWSWIRE) April 29, 2015 - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced that it has received CE-mark for CERAMENTT'V, the first injectable vancomycin eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.  CERAMENTT'V...
Novel formulation and proprietary patch pump would offer a new and different option for the management of fluid overload in heart failure.
Cambridge, UK - 21st April 2015: Acacia Pharma Ltd (Acacia Pharma" or "the Company"), the supportive care company developing  products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard antiemetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a...
OXFORD, UK - 16 April 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation Antibody Armed EnAd" (AbEnAd) anti-cancer therapeutic platform at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA April 19-22, 2015. AbEnAd is...
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications
Financing will be used to grow CERAMENTT platform and expand market penetration
1 3 4 5 6 7

News

DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge